Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Fig. 5

MEDI3039 prevented tumor metastasis outgrowth and extended animal survival in the MB231T experimental pulmonary metastasis model. a Design of the experiment. MEDI3039 (0.3 mg/kg) or vehicle was administered twice weekly, for 2 weeks. b Mice lung tissue from both vehicle- and MEDI3039-treated groups, fixed with Bouins’ solution. c Quantitative analysis of metastasized tumors in the lung. Total numbers of surface metastases (left) and large (> 3 mm) metastases (right) are shown. Data is presented as median with IQR. d Survival curve of mice treated with MEDI3039 (0.3 mg/kg) or vehicle. p value, HR, and 95% of CI were obtained with log-rank (Mantel–Cox) test, compared with the vehicle control group. e Representative images of H&E-stained lung tissue from vehicle- or MEDI3039-treated mouse. Scatter dot graph on the right shows quantitative analysis of microscopic tumors in the lung. Note that the vehicle group has only four samples, while the MEDI3039 group has five samples. One mouse in the vehicle group developed large confluent tumors covering the entire lung, making it difficult to count tumor numbers; therefore, the result is not included in the graph. Data is presented as median with IQR

Back to article page